Google
IMMX — IMMIX BIOPHARMA INC (Healthcare >> Biotechnology)
IMMX FAQ
What is IMMX's ROE?
IMMIX BIOPHARMA INC reports a Return on Equity (ROE) of -41.47%.
What is IMMX's dividend yield?
IMMIX BIOPHARMA INC offers a dividend yield of 0.00%.
What is IMMX's Deepscope Quality Score?
Deepscope rates IMMX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMMX?
Deepscope's AI Timing Score for IMMX is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMMX belong to?
IMMIX BIOPHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.37
Price
-0.86
(-9.27%)
Day Change
|
|
|---|
IMMX, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.37 |
| PBV / Sector |
7.10 / 4.53
|
| Earning Per Share | -0.49 |
| PE / Sector |
N/A / 16.80
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
12.18 M
GREAT
|
| Average 1W Daily Value |
10.91 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-03 09:10:53 |
| Symbol | IMMX |
| Name | IMMIX BIOPHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 71.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 599.06 / 8,614.17 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Phone: 310 651 8041
Website: https://www.immixbio.com
Sector: Healthcare >> Biotechnology
Description: Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
